Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 06, 2024, titled "Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting".